Neuroendocrine Tumor G2 — knowledge graph · CancerIndex

Knowledge graph · Cancer

Neuroendocrine Tumor G2

subtype

Identifier: CI-CAN-00003411
Entity page: /cancer/neuroendocrine-tumor-g2 ↗
Edges: 28

Neighbours: 8 drugs10 trials
Drawn: 18 of 18 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Neuroendocrine Tumor G2 investigated in trials for …INVESTIGATED_IN_TRIALSderived8 of 8
→ investigated in trials for	Lutetium (177lu) Oxodotreotideother 5 trials (4 active) · roll-up of the cancer and its descendants	—	—	Neuroendocrine Tumor G2	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Everolimussmall molecule 4 trials (3 active) · roll-up of the cancer and its descendants

Neuroendocrine Tumor G2 studied in …STUDIED_INderived10 of 20show all (up to 200)
→ studied in	NCT05773274Phase 2 · recruiting Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial · condition mapped CURATED_BROADER · 20 trials mapped (15 active)	—	—	Digestive System Neuroendocrine Tumor G2	1	Observed	clinicaltrials	graph →
→ studied in	NCT03375320Phase 3 · active not recruiting Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors · condition mapped ONTOLOGY_EXACT · 20 trials mapped (15 active)	—	—	Neuroendocrine Tumor G2	1	Observed	clinicaltrials	graph →
→ studied in	NCT04665739Phase 2 · recruiting Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors · condition mapped ONTOLOGY_EXACT · 20 trials mapped (15 active)	—	—	Lung Neuroendocrine Tumor G2	1	Observed	clinicaltrials	graph →
→ studied in	NCT00569127Phase 3 · active not recruiting Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor · condition mapped ONTOLOGY_EXACT · 20 trials mapped (15 active)	—	—	Neuroendocrine Tumor G2	1	Observed	clinicaltrials	graph →
→ studied in	NCT01841736Phase 2 · active not recruiting Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors · condition mapped ONTOLOGY_EXACT · 20 trials mapped (15 active)	—	—	Neuroendocrine Tumor G2	1	Observed	clinicaltrials	graph →
→ studied in	NCT06016855Phase 4 · recruiting Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors · condition mapped ONTOLOGY_EXACT · 20 trials mapped (15 active)	—	—	Digestive System Neuroendocrine Tumor G2	1	Observed	clinicaltrials	graph →
→ studied in	NCT03110978Phase 2 · active not recruiting Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer · condition mapped ALIAS · 20 trials mapped (15 active)	—	—	Lung Neuroendocrine Tumor G2	1	Observed	clinicaltrials	graph →
→ studied in	NCT04339036Phase 2 · recruiting CapTemY90 for Grade 2/3 NET Liver Metastases · condition mapped ALIAS · 20 trials mapped (15 active)	—	—	Neuroendocrine Tumor G2	1	Observed	clinicaltrials	graph →
→ studied in	NCT07150546Phase 1 · recruiting Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. · condition mapped CURATED_BROADER · 20 trials mapped (15 active)	—	—	Digestive System Neuroendocrine Tumor G2	1	Observed	clinicaltrials	graph →
→ studied in	NCT03879694Phase 1 · completed Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors · condition mapped ALIAS · 20 trials mapped (15 active)	—	—	Lung Neuroendocrine Tumor G2	1	Observed	clinicaltrials	graph →